



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

**NASDAQ: CELG**

Last Trade:	108.24
Trade Time:	4:00 PM ET Dec 14, 2017
Change:	0.04 (0.037%)
Day Range	107.95 - 109.52
52-Week Range	94.55 - 147.17
Volume	5,353,801

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Dec 11, 2017*  
[Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma](#)
- Dec 10, 2017*  
[Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting](#)
- Dec 7, 2017*  
[Long-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE® Vs. Solvent-Based Paclitaxel to Be Reported](#)
- Dec 5, 2017*  
[Celgene Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries](#)
- Nov 21, 2017*  
[Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American Society of Hematology Annual Meeting \(ASH\)](#)

**Financials** [\[ View all \]](#)

- Feb 10, 2017*  
[Annual Report \(10-K\)](#)
- Apr 27, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Oct 26, 2017*  
[Quarterly Report \(10-Q\)](#)
- Jul 27, 2017*  
[Quarterly Report \(10-Q\)](#)
- Apr 27, 2017*  
[Quarterly Report \(10-Q\)](#)

